摘要

Objectives: This presentation examines retrospective evidence on exosome application for hypertrophic scars, comparing it to conventional therapies such as corticosteroids, laser treatments, and silicone gels, which often show variable efficacy and recurrence rates. Evaluating exosomes’ role in modulating inflammation, collagen remodeling, and tissue regeneration, findings highlight their potential to improve scar texture, reduce hypertrophy, and enhance healing. These insights pave the way for integrating exosome therapy into future scar management protocols. Introduction: Hypertrophic scars remain a therapeutic challenge, with conventional treatments such as corticosteroids, lasers, and silicone gels often providing inconsistent results and high recurrence. This presentation examines retrospective clinical evidence on exosome therapy as a novel approach. By analyzing outcomes in comparison to established modalities, we explore how exosomes may address key limitations through their effects on inflammation, collagen remodeling, and regenerative signaling in scarred tissue. Materials / method: This multicenter, multipractitioner, and multimodal retrospective study reviewed patients treated for hypertrophic scars using topical exosome application following microneedling, fractional CO2, and other ablative laser treatments. Outcomes were compared to those of patients who received conventional therapies including corticosteroid injections, fractional lasers, and silicone-based products. Standardized photographs and physician assessments evaluated scar height, redness, pliability, and patient-reported satisfaction. Safety data were collected and reviewed across all modalities. Results: Subjects treated with exosomes demonstrated measurable improvements in scar texture, pliability, and height reduction earlier in the treatment timeline compared to those receiving conventional therapies. Redness was reduced more uniformly, and pliability scores improved across all modalities. These effects were consistent regardless of the delivery method used. Patient-reported satisfaction was notably higher in the exosome group. No adverse events were observed, supporting a strong safety and tolerability profile. Conclusion: This study supports exosome therapy as a promising addition to hypertrophic scar management. By targeting key regenerative pathways, exosomes improved scar outcomes more effectively and safely than many conventional options. The multimodal integration with microneedling and laser devices further enhanced their efficacy. These findings suggest that exosome therapy may redefine future protocols for scar treatment, offering a safe, versatile, and consistently effective alternative for improving long-term healing and tissue quality.